EGFR and renal cell carcinoma: However, Li et al. showed that reduced MARC2 expression was associated with an increased sensitivity to paclitaxel-based neoadjuvant therapy in human EGFR-2-negative breast cancer patients [37] but, to the best of our knowledge, there have been no previous reports on a role of MARC2 in RCC.